New drug has potential to treat broader range of cancers

September 10, 2012
New drug has potential to treat broader range of cancers

(Medical Xpress)—ImmuNext, founded by scientists at King's College London, has announced a  research and drug development agreement with Janssen Biotech Inc to develop a new cancer drug to trigger the body's own immune system to fight the disease.

The new therapy will be based on a discovery made by scientists at the MRC Centre for Transplantation at King's and Dartmouth Medical School (US), who identified a novel molecule in the immune system called VISTA, thought to be key to unlocking the body's own cancer-fighting response.

The NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London provided support to the project carried out at King's, which uncovered the role of  VISTA. VISTA naturally suppresses the immune system's response to and  limits a person's ability to kick-start the response needed to attack the disease. Drugs that block the function of VISTA have proven in pre-clinical models to enhance cancer immunity and reduce . It is anticipated that blocking VISTA in will allow the body to trigger a protective immune response to cancer with the ultimate goal of .

While there are already drugs in early development to unlock the body's own immune system to attack cancer cells, it is thought that the inhibition of VISTA has the potential to treat a much broader range of solid and liquid cancers.

ImmuNext will grant Janssen a worldwide exclusive license to develop and commercialise therapies that suppress VISTA.

Professor Randolph Noelle, MRC Centre for Transplantation at King's and Chief Scientific Officer at ImmuNext, said: 'This is an extremely exciting development in the fight against cancer. We have discovered a new that could allow us to unleash a patient's own immune response to attack and eradicate the disease.

'We are delighted to be working with Jenssen to turn this discovery into real treatments for cancer patients.

'Immunotherapy has taken centre stage in the cure for cancer, and VISTA represents the newest, and one of the most exciting novel targets in this approach.'

Related Stories

Immune cell can trigger skin cancer caused by toxins

January 9, 2012

(Medical Xpress) -- Researchers based jointly at King’s College London and the Cancer Research UK London Research Institute, together with collaborators at Yale University have found that a type of immune cell, called ...

Recommended for you

New treatment options for a fatal leukemia

July 27, 2015

In industrialized countries like in Europe, acute lymphoblastic leukemia is the most common form of cancer in children. An international research consortium lead by pediatric oncologists from the Universities of Zurich and ...

Exciting results from cancer immunoagent study

July 20, 2015

(Medical Xpress)—Cancer therapies have improved incrementally over the years, but cancer treatment largely remains analogous to forest fire suppression, in which the spread of fire is contained with deliberate controlled ...

Modified DNA building blocks are cancer's Achilles heel

July 22, 2015

In studying how cells recycle the building blocks of DNA, Ludwig Cancer Research scientists have discovered a potential therapeutic strategy for cancer. They found that normal cells have highly selective mechanisms to ensure ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.